Equity Research on Spectrum Pharmaceuticals Inc. and Amgen Inc. - Biotechnology Companies Releasing Strong Earnings
(firmenpresse) - NEW YORK, NY -- (Marketwire) -- 05/04/12 -- has a handpicked team of market professionals with over 100 years of combined investing experience. Today they are providing members comprehensive research on the Biotechnology industry and are offering free analytical research on (NASDAQ: SPPI) and (NASDAQ: AMGN). Register with us today at to have free access to these research reports.
There have been some positive first quarter results coming out of the healthcare biotechnology industry. Spectrum Pharmaceuticals Inc. recently reported first quarter earnings per share of $0.71, well above year ago earnings of $0.23 per share. Revenues also increased above year ago levels of $44 million, reaching $60 million. Get your free reports on and at . There is no commitment to join.
is the Ultimate Trading Environment for investors. If you are considering owning Spectrum Pharmaceuticals Inc. and Amgen Inc. then you should sign up for a free membership and our complimentary reports today at . Over the last 5 years our returns outpaced any of the major indexes. Sign up today to find out what you are missing.
Spectrum has also newly announced its decision to bump up its U.S. manufacturing capacity of Fusilev which was recently approved as a treatment for colorectal cancer. report is accessible for free by registering today at .
Year-over-year improvements could also be seen in the first quarter report of Amgen Inc. Earnings per share at Amgen were $1.59 per share, 20.5 percent higher than a year ago. Total revenues increased by 9.2 and a lower tax rate and share count were also positives. Amgen has been working hard to expand its international reach and market share, with plans to have operations in 75 countries by 2015. Most recently it has agreed to acquire 95.6 percent of shares of Turkish company Mustafa Nevzat Pharmaceuticals. report is accessible for free by registering today at .
The two stocks research reports are available for free by signing up now on .
Shine's Rooms is the brain child of David Shine, a 13 year Wall Street veteran with a stellar track record. For 13 years Shine has trained thousands of traders to navigate and profit from the markets. Using cutting edge technology, Shine provides you with a community in which you can trade alongside Shine and his Team as they guide you through the market's ever-changing landscape.
To view our visit this link .
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 04.05.2012 - 12:05 Uhr
Sprache: Deutsch
News-ID 142807
Anzahl Zeichen: 0
contact information:
Town:
NEW YORK, NY
Kategorie:
Commercial & Investment Banking
Diese Pressemitteilung wurde bisher 153 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Equity Research on Spectrum Pharmaceuticals Inc. and Amgen Inc. - Biotechnology Companies Releasing Strong Earnings"
steht unter der journalistisch-redaktionellen Verantwortung von
Shinesrooms.com (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
